Tima Dehghani1, Phung N Thai2, Harkanwalpreet Sodhi1, Lu Ren2, Padmini Sirish2, Carol E Nader2, Valeriy Timofeyev2, James L Overton2, Xiaocen Li3, Kit S Lam3, Nipavan Chiamvimonvat2,4,5, Alyssa Panitch1,6. 1. Department of Biomedical Engineering, University of California, 451 Health Sciences Drive, GBSF 2303, Davis, CA 95616, USA. 2. Department of Internal Medicine, Division of Cardiovascular Medicine, University of California, Davis, CA, USA. 3. Department of Biochemistry and Molecular Medicine, University of California, Davis, CA, USA. 4. Department of Veterans Affairs, Northern California Health Care System, Mather, CA, USA. 5. Department of Pharmacology, University of California, Davis, CA, USA. 6. Department of Surgery, University of California, Davis, CA, USA.
Abstract
AIMS: One of the hallmarks of myocardial infarction (MI) is excessive inflammation. During an inflammatory insult, damaged endothelial cells shed their glycocalyx, a carbohydrate-rich layer on the cell surface which provides a regulatory interface to immune cell adhesion. Selectin-mediated neutrophilia occurs as a result of endothelial injury and inflammation. We recently designed a novel selectin-targeting glycocalyx mimetic (termed DS-IkL) capable of binding inflamed endothelial cells. This study examines the capacity of DS-IkL to limit neutrophil binding and platelet activation on inflamed endothelial cells, as well as the cardioprotective effects of DS-IkL after acute myocardial infarction. METHODS AND RESULTS: In vitro, DS-IkL diminished neutrophil interactions with both recombinant selectin and inflamed endothelial cells, and limited platelet activation on inflamed endothelial cells. Our data demonstrated that DS-IkL localized to regions of vascular inflammation in vivo after 45 min of left anterior descending coronary artery ligation-induced MI. Further, findings from this study show DS-IkL treatment had short- and long-term cardioprotective effects after ischaemia/reperfusion of the left anterior descending coronary artery. Mice treated with DS-IkL immediately after ischaemia/reperfusion and 24 h later exhibited reduced neutrophil extravasation, macrophage accumulation, fibroblast and endothelial cell proliferation, and fibrosis compared to saline controls. CONCLUSIONS: Our findings suggest that DS-IkL has great therapeutic potential after MI by limiting reperfusion injury induced by the immune response. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: One of the hallmarks of myocardial infarction (MI) is excessive inflammation. During an inflammatory insult, damaged endothelial cells shed their glycocalyx, a carbohydrate-rich layer on the cell surface which provides a regulatory interface to immune cell adhesion. Selectin-mediated neutrophilia occurs as a result of endothelial injury and inflammation. We recently designed a novel selectin-targeting glycocalyx mimetic (termed DS-IkL) capable of binding inflamed endothelial cells. This study examines the capacity of DS-IkL to limit neutrophil binding and platelet activation on inflamed endothelial cells, as well as the cardioprotective effects of DS-IkL after acute myocardial infarction. METHODS AND RESULTS: In vitro, DS-IkL diminished neutrophil interactions with both recombinant selectin and inflamed endothelial cells, and limited platelet activation on inflamed endothelial cells. Our data demonstrated that DS-IkL localized to regions of vascular inflammation in vivo after 45 min of left anterior descending coronary artery ligation-induced MI. Further, findings from this study show DS-IkL treatment had short- and long-term cardioprotective effects after ischaemia/reperfusion of the left anterior descending coronary artery. Mice treated with DS-IkL immediately after ischaemia/reperfusion and 24 h later exhibited reduced neutrophil extravasation, macrophage accumulation, fibroblast and endothelial cell proliferation, and fibrosis compared to saline controls. CONCLUSIONS: Our findings suggest that DS-IkL has great therapeutic potential after MI by limiting reperfusion injury induced by the immune response. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Sean M Davidson; Péter Ferdinandy; Ioanna Andreadou; Hans Erik Bøtker; Gerd Heusch; Borja Ibáñez; Michel Ovize; Rainer Schulz; Derek M Yellon; Derek J Hausenloy; David Garcia-Dorado Journal: J Am Coll Cardiol Date: 2019-01-08 Impact factor: 24.094
Authors: Marilyn J Telen; Ted Wun; Timothy L McCavit; Laura M De Castro; Lakshmanan Krishnamurti; Sophie Lanzkron; Lewis L Hsu; Wally R Smith; Seungshin Rhee; John L Magnani; Helen Thackray Journal: Blood Date: 2015-03-02 Impact factor: 22.113
Authors: Yaqin Xu; Yuqing Huo; Marie-Claire Toufektsian; Susan I Ramos; Yongguang Ma; Ankit D Tejani; Brent A French; Zequan Yang Journal: Am J Physiol Heart Circ Physiol Date: 2005-09-30 Impact factor: 4.733
Authors: Markus Rehm; Dirk Bruegger; Frank Christ; Peter Conzen; Manfred Thiel; Matthias Jacob; Daniel Chappell; Mechthild Stoeckelhuber; Ulrich Welsch; Bruno Reichart; Klaus Peter; Bernhard F Becker Journal: Circulation Date: 2007-10-08 Impact factor: 29.690
Authors: Edmund Y M Chung; Katie Trinh; Jennifer Li; Sebastian Hayden Hahn; Zoltan H Endre; Natasha M Rogers; Stephen I Alexander Journal: Front Cardiovasc Med Date: 2022-05-20